



# 30-Day Countdown – Reinstatement of Prior Authorization Requirements for 39 Drug Classes

December 20, 2022

## What is Happening?

On January 20, 2023, prior authorization (PA) requirements will be reinstated for 39 additional drug classes for new start medications for beneficiaries 22 years of age and older. “New starts” are defined as new therapies or medications not previously prescribed to the beneficiary during the 15-month lookback period. Historical claims data and PAs will be used to review for grandfathering.

- New start prescriptions for beneficiaries 21 years of age and younger within these 39 drug classes will not be subject to PA reinstatement.

**Note:** For prescriptions requiring a PA that either do not have an approved PA or a historical claim on file, PA requirements will remain in place.


**Do not submit PA requests prior to January 20, 2023, for a medication in one of the following 39 Standard Therapeutic Classes (STCs) that will require a PA.** PA requests submitted prior to January 20, 2023, will be returned with a message that no PA is required.

Phase II, Wave I Drug Classes		
All Other Dermatologicals	Corticotropins	Other Antibiotics
Anabolics	Emollients Protectives	Other Hormones
Androgens	Erythromycins	Penicillins
Anesthetic Local, Topical	Estrogens	Progesterone
Antiarthritics	Fat Soluble Vitamins	Streptomycins

Phase II, Wave I Drug Classes		
Antifungals	Folic Acid Preparations	Sulfonamides
Antimalarials	General Antibacterials and Antiseptics	Systemic Contraceptives
Antiparasitics	Glucocorticoids	TB Preparations
Antiparkinson	Iodine Therapy	Tetracyclines
Anti-Ulcer Preps/Gastrointestinal Preps	Multivitamins	Thyroid Preps
Antivirals	Muscle Relaxants	Topical Nasal and Otic Preparations
Biologicals	Non-Opioid Analgesics	Urinary Antibacterials
Cephalosporins	Ophthalmic Preparations	Vitamin K

**Note:** For drug classes either not listed above or not reinstated during Phase I, Wave III, the PA requirements will remain temporarily suspended. Medi-Cal Rx will continue to utilize PA and claims data to allow for grandfathering of previously approved PAs after July 2, 2022.

PAs that are submitted prior to the transition policy being phased out for beneficiaries currently on a drug therapy and covered under the transition policy **will not** be accepted at this time.



- When prescribing a drug in one of these drug classes for a patient who has not been on the drug over the last 15 months, check the [Covered Products List](#).
- For beneficiaries already on a drug therapy for qualified or “grandfathered” drugs, the transition policy will continue to allow access to care.

## Next Steps

- For more information, visit the [Medi-Cal Rx Education & Outreach](#) page on the [Medi-Cal Rx Web Portal](#) and select **Reinstatement** from the left-hand menu.
- Review the [Medi-Cal Rx Reinstatement of Prior Authorizations and Retirement of the Transition Policy: Phases II, III, and IV](#) presentation.
- Refer to the [Medi-Cal Rx Bulletins & News](#) and [Medi-Cal Rx Forms & Information](#) pages of the [Medi-Cal Rx Web Portal](#) for guidance to successfully submit PAs.
- Assess business processes and workflows to account for the reinstatement of PA edits for the drug classes.

## Contact Information

You can call the Medi-Cal Rx Customer Service Center (CSC) at 1-800-977-2273, which is available 24 hours a day, 7 days a week, 365 days per year.

For other questions, email Medi-Cal Rx Education & Outreach at [MediCalRxEducationOutreach@magellanhealth.com](mailto:MediCalRxEducationOutreach@magellanhealth.com).